IQVIA Holdings Inc. (IQV)
|52 Week Range||165.75-249.11|
|1y Target Est||-|
|DCF Unlevered||IQV DCF ->|
|DCF Levered||IQV LDCF ->|
|Debt / Equity||333.90%||Strong Buy|
Upgrades & Downgrades
Latest IQV news
Why You Should Retain IQVIA Holdings (IQV) Stock for Now
7 June 2023
IQVIA Holdings' (IQV) enormous treasure trove of information is a distinguishing asset and also perhaps a big barrier to entry for competitors.
IQVIA's (IQV) Extensive Database Blocks New Entrants
23 May 2023
A strong database of patient records and a huge market are tailwinds for IQVIA's (IQV) success.
IQVIA Holdings: A Possible Beat And Raise Scenario In The Works
23 May 2023
Despite some concerns about TAS performance, overall demand remains robust. While TAS performance was weak in the first quarter, it is expected to recover in the second half of the year.
3 Stocks to Watch From a Promising Technology Services Industry
5 May 2023
The Zacks Technology Services industry seeks to benefit from increased digitization and dependency on technology, and the growing adoption of the multi-cloud model. TT, IQV and TSP are well-positioned...
13 Stocks Pay You Very Well To Stay Invested In May
2 May 2023
Thinking about selling in May and staying away from the S&P 500? Not so fast.
IQVIA Holdings (IQV) Surpasses Q1 Earnings & Revenue Estimates
27 April 2023
IQVIA Holdings (IQV) first-quarter 2023 revenues improve year over year.
IQVIA Holdings (IQV) Tops Q1 Earnings and Revenue Estimates
27 April 2023
IQVIA Holdings (IQV) came out with quarterly earnings of $2.45 per share, beating the Zacks Consensus Estimate of $2.41 per share. This compares to earnings of $2.47 per share a year ago.
Here's Why Investors Should Retain IQVIA Holdings (IQV) Stock
11 April 2023
Market size and data reserve are positives for IQVIA Holdings (IQV). Foreign currency risk is bothersome.
IQVIA to Announce First-Quarter 2023 Results on April 27, 2023
6 April 2023
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its first-quarter 2023 financial results before the market opens on Thursday, April 27, 2023. The ...
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >